Area of research
Rheumatology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Vasculitis and related conditions, Otitis Media and Relapsing Polychondritis, Histiocytic Disorders and Treatments, and Systemic Lupus Erythematosus Research.
American College of Rheumatology Guidance Statement for Diagnosis and Management of <scp>VEXAS</scp> Developed by the International <scp>VEXAS</scp> Working Group Expert Panel
Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants
Venous and arterial thrombosis in patients with VEXAS syndrome
Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms
Spectrum of clonal hematopoiesis in VEXAS syndrome
<i>BRAF</i> V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Long-term outcomes among adults with Langerhans cell histiocytosis
Neurological Manifestations of Histiocytic Disorders
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
The provisional OMERACT ultrasonography score for giant cell arteritis
Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on <i>KRAS</i> and <i>MEK</i> Alteration Status
Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp>‐mutated Erdheim–Chester disease
Classical and <scp>non‐classical</scp> phenotypes of <scp>Erdheim–Chester</scp> disease: Correlating clinical, radiographic and genotypic findings
Ophthalmologic Involvement in Adults with Histiocytic Disorders
Efficacy of MEK Inhibitors in Erdheim Chester Disease
Clinical Heterogeneity of the VEXAS Syndrome
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival
Efficacy of BRAF-Inhibitor Therapy in <i>BRAF</i> <i>V600E</i>-Mutated Adult Langerhans Cell Histiocytosis
Low-dose vemurafenib monotherapy in <i>BRAF<sup>V600E</sup></i>-mutated Erdheim-Chester disease
Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises